CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
INHALED TB BOOSTER OBTAINS CLINICAL TRIAL APPROVAL IN INDONESIA

This announcement is made by CanSino Biologics Inc. (the "**Company**") on a voluntary basis.

The Company is pleased to announce that it has obtained Phase I clinical trial approval granted by the Badan Pengawas Obat dan Makanan, Republik Indonesia to initiate relevant clinical trial for the inhaled tuberculosis vaccine (Adenovirus Type 5 Vector) ("**inhaled TB Booster**") developed by the Company.

According to the Global Tuberculosis Report 2024 published by the World Health Organization ("**WHO**"), there were 10.8 million new cases of tuberculosis globally in 2023, with a slight increase from 10.7 million cases in 2022, and higher than the 10.4 million cases in 2021 and 10.1 million cases in 2020. Geographically, most tuberculosis cases occurred in 2023 were in the WHO Regions of South-East Asia (45%), Africa (24%) and the Western Pacific (17%). The 30 high tuberculosis burden countries accounted for 87% of all estimated incident cases worldwide, with eight of these countries accounting for more than two thirds of the global total: India (26%), Indonesia (10%), China (6.8%), Philippines (6.8%), Pakistan (6.3%), Nigeria (4.6%), Bangladesh (3.5%) and the Democratic Republic of the Congo (3.1%).

Currently, Bacillus Calmette-Guerin is the only available tuberculosis vaccine in the world and is widely vaccinated globally, playing an important role in the prevention of tuberculosis in infants and children. However, the efficacy of Bacillus Calmette-Guerin declines over time and it is unable to enhance vaccine protection through booster dose for vaccination. To address this deficiency, the Company has developed the first generation of a globally innovative tuberculosis booster vaccine ("**TB Booster**") for the Bacillus Calmette-Guerin-vaccinated population. The Phase Ia and Phase Ib clinical trials for TB Booster were completed in Canada, and the clinical trial data demonstrated its safety and its effectiveness as a Bacillus Calmette-Guerin booster vaccine, as well as its superiority of mucosal immunity.

Based on the accumulation of technology in the development of COVID-19 vaccine for inhalation, the Company has established a complete inhalation pharmacy and quality control system, upgraded the first generation of product, and also increased the antigen components to develop inhaled TB Booster, which is delivered through aerosol inhalation, and it is expected to be able to stimulate the immune response in lungs, so as to clear tuberculosis bacilli and control latent infection, and to achieve the effect of preventing infections.

The purpose of the Phase I clinical trial is to investigate the safety and immunogenicity of a single dose of inhaled TB Booster in adults aged 18 to 49 years.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 15, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.